

Takuya Osada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7862857/publications.pdf>

Version: 2024-02-01

31
papers

1,346
citations

430874

18
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

2353
citing authors

#	ARTICLE	IF	CITATIONS
1	HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 217-226.	4.1	2
2	Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. , 2022, 10, e003717.		27
3	Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-“PD-1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 2481-2493.	7.0	33
4	Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. <i>Communications Biology</i> , 2020, 3, 226.	4.4	18
5	Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. <i>Immunotherapy</i> , 2019, 11, 953-966.	2.0	8
6	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.	7.0	50
7	Nicosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy. <i>Biochemical Journal</i> , 2019, 476, 535-546.	3.7	44
8	Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 9-11.	7.0	10
9	Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. <i>Breast Cancer Research</i> , 2018, 20, 90.	5.0	14
10	A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy <i><i>in Vivo</i></i> . <i>ACS Chemical Biology</i> , 2017, 12, 1047-1055.	3.4	40
11	Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. <i>Onc Immunology</i> , 2017, 6, e1315495.	4.6	17
12	<i><i>In Vivo</i></i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. <i>Clinical Cancer Research</i> , 2017, 23, 7531-7542.	7.0	15
13	Preclinical Evaluation of ¹⁸ F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2016, 57, 967-973.	5.0	68
14	X-Ray Psoralen Activated Cancer Therapy (X-PACT). <i>PLoS ONE</i> , 2016, 11, e0162078.	2.5	23
15	CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 677-688.	4.2	75
16	Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3081-3081.	1.6	4
17	N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization. <i>Nuclear Medicine and Biology</i> , 2014, 41, 802-812.	0.6	19
18	Functional genomic screens and identification of signaling pathways in oxaliplatin-resistance in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3611-3611.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells. <i>Chemistry and Biology</i> , 2013, 20, 1187-1197.	6.0	43
20	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 391-397.	0.5	9
21	Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1500-1509.	4.1	36
22	Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1941-1951.	4.2	22
23	Novel Recombinant Alphaviral and Adenoviral Vectors for Cancer Immunotherapy. <i>Seminars in Oncology</i> , 2012, 39, 305-310.	2.2	14
24	Effect of the loss of the type III TGF β 2 receptor during tumor progression on tumor microenvironment: Preclinical development of TGF β 2 inhibition and TGF β 2-related biomarkers to enhance immunotherapy efficacy. <i>Journal of Clinical Oncology</i> , 2012, 30, 10563-10563.	1.6	3
25	Effect of the vaccine Ad5 [E1-, E2b-]-CEA(6D) on CEA-directed CMI responses in patients with advanced CEA-expressing malignancies in a phase I/II clinical trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2585-2585.	1.6	38
26	Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations. <i>Cancer Research</i> , 2011, 71, 4172-4182.	0.9	239
27	Induction of Wilms' Tumor Protein (WT1)â€“Specific Antitumor Immunity Using a Truncated WT1-Expressing Adenovirus Vaccine. <i>Clinical Cancer Research</i> , 2009, 15, 2789-2796.	7.0	13
28	The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1115-1124.	4.2	271
29	Dendritic Cell-Based Immunotherapy. <i>International Reviews of Immunology</i> , 2006, 25, 377-413.	3.3	93
30	NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1122-1131.	4.2	63
31	Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. <i>International Immunology</i> , 2005, 17, 1143-1155.	4.0	35